BIO 2016 Notebook: Dealmaking, Reputation, Thailand And Boehringer Beyond Borders

During the final days of the BIO International Convention, we heard about trends in biopharma deals for 2016, a call to arms for individuals to do more to communicate the industry's positive impact, and anticipated reforms in Thailand.

business

inVentiv Health Consulting MD Neel Patel, presenting results of the firm's annual survey of industry dealmakers' intentions at a session on June 9 – the final day of BIO – shared data on the varying levels of buyer demand versus asset availability from sellers. Antibiotics emerged as the area with the greatest demand surplus, with pain, CNS and gastrointestinal indications also evident as strong markets for sellers, while supply now looks to be outstripping demand in oncology, hepatic indications and dermatology.

Overall, 2016 looks like a seller's market, particularly for firms with later-stage assets to partner, license or sell. However, total...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.